Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
117.2 SEK | +0.17% | +5.78% | -7.79% |
Sales 2024 * | 1.88B 175M | Sales 2025 * | 3.16B 295M | Capitalization | 6.29B 587M |
---|---|---|---|---|---|
Net income 2024 * | 85M 7.93M | Net income 2025 * | 1.09B 102M | EV / Sales 2024 * | 3.28 x |
Net cash position 2024 * | 125M 11.69M | Net cash position 2025 * | 1.21B 113M | EV / Sales 2025 * | 1.61 x |
P/E ratio 2024 * |
27.7
x | P/E ratio 2025 * |
5.08
x | Employees | 217 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.29% |
Latest transcript on Calliditas Therapeutics AB
1 day | +0.17% | ||
1 week | +5.78% | ||
Current month | +6.55% | ||
1 month | +14.90% | ||
3 months | +6.64% | ||
6 months | +27.74% | ||
Current year | -7.79% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 1 M€ | 0.00% | - | |
0.00% | 29 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 117.2 | +0.17% | 105,655 |
24-05-16 | 117 | -1.27% | 221,666 |
24-05-15 | 118.5 | -3.42% | 166,440 |
24-05-14 | 122.7 | +6.42% | 335,794 |
24-05-13 | 115.3 | +4.06% | 184,669 |
Delayed Quote Nasdaq Stockholm, May 17, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.79% | 587M | |
+16.03% | 79.03B | |
+10.23% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.83% | 2.3B | |
-29.65% | 2.21B | |
+19.51% | 2.17B |
- Stock Market
- Equities
- CALTX Stock